Sarah Price1, Brian Hitsman2,3, Anna Veluz-Wilkins2, Sonja Blazekovic1, Tarah R Brubaker1, Frank Leone4, Anita Hole1, E Paul Wileyto5, Corey Langer6, Ravi Kalhan2,7, Jyoti Patel3,7, Robert Schnoll1. 1. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Presbyterian Medical Center, Philadelphia, PA, USA. 5. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Medicine, University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA, USA. 7. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
BACKGROUND: Continuing to smoke after a cancer diagnosis can adversely influence the prognosis for patients with cancer. However, remarkably few studies have carefully examined the use of first-line FDA-approved medications for nicotine dependence in patients with cancer. This study evaluated the feasibility, safety, and effect on cessation of varenicline for smoking cessation in patients with cancer. METHODS: Data from 132 treatment-seeking smokers who received 12 weeks of open-label varenicline and five brief behavioral counseling sessions were used to evaluate the feasibility, safety, and impact on cessation of varenicline. The effects of abstinence on cognitive function and affect were also explored. RESULTS: Of 459 patients screened, 306 were eligible for the study (66.7%) and 132 entered treatment (43.1%). Retention was 84.1% over 12 weeks. The rate of biochemically verified abstinence at week 12 was 40.2%. Expected side effects were reported (e.g. sleep problems, nausea), but there were no reports of elevated depressed mood, suicidal thoughts, or cardiovascular events. Abstinence was associated with improved cognitive function and reduced negative affect over time (p < 0.05). CONCLUSIONS: Although many patients with cancer who smoke did not enroll in treatment, the side effect profile of varenicline and its effect on short-term cessation converge with what is seen in the general population. Further, as with the general population, abstinence while taking varenicline may lead to improved cognitive function and reduced negative affect. The present data support the use of varenicline to help patients with cancer to quit smoking.
BACKGROUND: Continuing to smoke after a cancer diagnosis can adversely influence the prognosis for patients with cancer. However, remarkably few studies have carefully examined the use of first-line FDA-approved medications for nicotinedependence in patients with cancer. This study evaluated the feasibility, safety, and effect on cessation of varenicline for smoking cessation in patients with cancer. METHODS: Data from 132 treatment-seeking smokers who received 12 weeks of open-label varenicline and five brief behavioral counseling sessions were used to evaluate the feasibility, safety, and impact on cessation of varenicline. The effects of abstinence on cognitive function and affect were also explored. RESULTS: Of 459 patients screened, 306 were eligible for the study (66.7%) and 132 entered treatment (43.1%). Retention was 84.1% over 12 weeks. The rate of biochemically verified abstinence at week 12 was 40.2%. Expected side effects were reported (e.g. sleep problems, nausea), but there were no reports of elevated depressed mood, suicidal thoughts, or cardiovascular events. Abstinence was associated with improved cognitive function and reduced negative affect over time (p < 0.05). CONCLUSIONS: Although many patients with cancer who smoke did not enroll in treatment, the side effect profile of varenicline and its effect on short-term cessation converge with what is seen in the general population. Further, as with the general population, abstinence while taking varenicline may lead to improved cognitive function and reduced negative affect. The present data support the use of varenicline to help patients with cancer to quit smoking.
Authors: Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale Journal: Lancet Respir Med Date: 2015-01-12 Impact factor: 30.700
Authors: Kelly Posner; Gregory K Brown; Barbara Stanley; David A Brent; Kseniya V Yershova; Maria A Oquendo; Glenn W Currier; Glenn A Melvin; Laurence Greenhill; Sa Shen; J John Mann Journal: Am J Psychiatry Date: 2011-12 Impact factor: 18.112
Authors: Robert M Anthenelli; Chad Morris; Tanya S Ramey; Sarah J Dubrava; Kostas Tsilkos; Cristina Russ; Carla Yunis Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Jonathan Foulds; Cristina Russ; Ching-Ray Yu; Kelly H Zou; Aaron Galaznik; Mikael Franzon; Arthur Berg; John R Hughes Journal: Nicotine Tob Res Date: 2013-05-21 Impact factor: 4.244
Authors: Nancy A Rigotti; Andrew L Pipe; Neal L Benowitz; Carmen Arteaga; Dahlia Garza; Serena Tonstad Journal: Circulation Date: 2010-01-04 Impact factor: 29.690
Authors: Grace Crawford; Jessica Weisbrot; Joseph Bastian; Alex Flitter; Nancy C Jao; Allison Carroll; Ravi Kalhan; Frank Leone; Brian Hitsman; Robert Schnoll Journal: Nicotine Tob Res Date: 2019-07-17 Impact factor: 4.244
Authors: Rebecca L Ashare; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Anita Hole; Karam Mounzer; Ronald G Collman; E Paul Wileyto; Robert Schnoll Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Robert Schnoll; Frank Leone; Anna Veluz-Wilkins; Andrew Miele; Anita Hole; Nancy C Jao; E Paul Wileyto; Allison J Carroll; Ravi Kalhan; Jyoti Patel; Corey Langer; Su Fen Lubitz; Brian Hitsman Journal: Psychooncology Date: 2019-01-24 Impact factor: 3.894
Authors: Mackenzie Hosie Quinn; Anna-Marika Bauer; Alex Flitter; Su Fen Lubitz; Rebecca L Ashare; Morgan Thompson; Frank Leone; Robert Gross; Robert Schnoll Journal: Addict Behav Date: 2019-10-22 Impact factor: 3.913
Authors: Morgan Thompson; Robert Schnoll; Katrina Serrano; Frank Leone; Robert Gross; Ronald G Collman; Rebecca L Ashare Journal: Psychopharmacology (Berl) Date: 2020-01-14 Impact factor: 4.530